Skip to main content

Displaying 1 - 1 of 1

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Multiple Cancer Types

This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants
with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this
study will be to investigate the recommended dose of R-DXd that can be given safely to
participants, assess the side effects of R-DXd, and evaluate the effectiveness of R-DXd.
Kidney (Renal Cell), Ovarian, Phase I
I
Rini, Brian
NCT04707248
VICCPHI2115